Hutchmed Share News (HCM)

Hutchmed China confident after being added to SEC list

(Sharecast News) - Hutchmed China updated the market on its status under the United States 'Holding Foreign Companies Accountable Act' on Thursday.

AIM WINNERS & LOSERS: Omega Diagnostics Visitect not available in UK

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

IN BRIEF: Hutchmed China shares fall as US listing under threat

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Says its depositary shares may be delisted from New York's Nasdaq exchange in early 2024 unless the Holding Foreign Companies Accountable Act is amended to exclude Hutchmed. The act is part of regulatory focus in the US on access to audit and other information. It requires the US Securities & Exchange Commission to prohibit the securities of any company from being traded on any of the US securities exchanges if the auditor of the company's financial statements is not subject to inspection by the US Public Co Accounting Oversight Board for three consecutive years. Another way for Hutchmed to be excluded from the act is if the PCAOB is able to conduct a full inspection of the company's auditor during the required timeframe.

Hutchmed receives USD15 million from AstraZeneca for Saffron progress

(Alliance News) - Hutchmed (China) Ltd on Monday said it has received USD15 million from AstraZeneca PLC as start-up activities for Saffron commenced.

EARNINGS REPORTS: Elementis swings to profit; Hutchmed changes CEO

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Hutchmed China losses widen as it appoints new CEO

(Sharecast News) - Hutchmed China reported a 56% increase in total revenues in its full-year results on Thursday, to $356.1m (£266.17m), although its losses widened, as it announced the departure of its chief executive officer and the appointment of his replacement.

TRADING UPDATES: Hutchmed in Macau boost; UP Global success in Germany

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

Hutchmed starts new phase of probe on HMPL-453 as combination therapy

Hutchmed starts new phase of probe on HMPL-453 as combination therapy

Hutchmed begins phase one study for potential tumour treatment

Hutchmed begins phase one study for potential tumour treatment

TOP NEWS: Retailer ASOS now to be seen on London Main Market

TOP NEWS: Retailer ASOS now to be seen on London Main Market

Hutchmed gains breakthrough therapy designation in China for HMPL-523

Hutchmed gains breakthrough therapy designation in China for HMPL-523

Hutchmed begins phase one study for potential cancer treatment

Hutchmed begins phase one study for potential cancer treatment

Hutchmed completes patient enrolment for cancer drug study

Hutchmed completes patient enrolment for cancer drug study

Two Hutchmed drugs included in China's 2022 reimbursement list

(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.